Advertisement

Tumor Biology

, Volume 35, Issue 5, pp 4295–4299 | Cite as

Possible relations between oxidative damage and apoptosis in benign prostate hyperplasia and prostate cancer patients

  • Funda Kosova
  • Gökhan Temeltaş
  • Zeki Arı
  • Murat Lekili
Research Article

Abstract

Cancer has been described as the twentieth century plague, and is a very common health problem. It has been reported that ROS and ROS products play a key role in cancer and that oxidative damage is effective in apoptosis initiation. In this study we aimed to evaluate the relationship between MDA (malondialdehyde), DNA damage (8-hydroxyguanine, 8-OH-dG), and caspase-3 in BHP and prostate cancer patients. Twenty male patients with prostate cancer and 20 male patients with benign prostate hyperplasia were included into this study. The MDA (nanomole), DNA damage (nanograms per millilitre), and caspase-3 (nanograms per millilitre) levels were measured in prostate cancer and benign prostate hyperplasia using Elisa kits (Millipore Corporation, Billerica, MA, USA). In the prostate cancer group, serum MDA (30.96 ± 9.25) and DNA damage (4.42 ± 0.36) levels were significantly raised (p < 0.05) when compared to the benign prostate hyperplasia group (24.05 ± 8.06, 3.99 ± 0.54). However, in the prostate cancer group, serum caspase-3 (2.36 ± 0.82) levels were statistically significantly lowered (p < 0.05) compared with the benign prostate hyperplasia group (3.15 ± 1.04). We observed that altered prooxidant, DNA damage levels may lead to an increase in oxidative damage and may consequently play an important role in prostate carcinogenesis. These findings indicate that, although the triggering of these changes is unknown, changes in the levels of MDA, DNA damage, and caspase-3 in the blood are related to prostatic carcinoma development. In addition, it would be appropriate to conduct new studies with a large number of patients at different stages.

Keywords

Prostate cancer Benign prostate hyperplasia Apoptosis DNA damage 

Notes

Conflicts of interest

None

References

  1. 1.
    Funda Kosova, Zeki Arı, Prostate kanseri ve apoptozis, Journal of Clinical and Experimental Investigations, , cilt2(1), 124-131, Mart 2011.Google Scholar
  2. 2.
    Fenech M, Ferguson LR. Vitamins/minerals and genomic stability in humans. Mutat Res. 2001;475:1–6.CrossRefPubMedGoogle Scholar
  3. 3.
    Burcham PC. Internal hazards: baseline DNA damage by endogenous products of normal metabolism. Mutat Res. 1999;443:11–36.CrossRefPubMedGoogle Scholar
  4. 4.
    Forsberg L, de Faire U, Morgenstern R. Oxidative stress, human genetic variation, and disease. Arch Biochem Biophys. 2001;389:84–93.CrossRefPubMedGoogle Scholar
  5. 5.
    Bredesen DE. Neural apoptosis. Ann Neurol. 1995;38:839–51.CrossRefPubMedGoogle Scholar
  6. 6.
    Kroemer G, Zamzami N, Susin SA. Mitochondrial control of apoptosis. Immunol Today. 1997;18:44–51.CrossRefPubMedGoogle Scholar
  7. 7.
    D’Mello SR. Molecular regulation of neuronal apoptosis. Curr Top Dev Biol. 1998;39:187–213.CrossRefPubMedGoogle Scholar
  8. 8.
    Greenlund LJ, Deckwerth TL, Johnson Jr EM. Superoxide dismutase delays neuronal apoptosis: a role for reactive oxygen species in programmed neuronal death. Neuron. 1995;14:303–15.CrossRefPubMedGoogle Scholar
  9. 9.
    Hockenbery D, Oltvai ZN, Yin XM, Milliman CL, Korsmeyer SH. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell. 1993;75:241–51.CrossRefPubMedGoogle Scholar
  10. 10.
    Keller JN, Kindy MS, Holtsberg FW, St. Clair DK, Yen HC, Germeyer A, et al. Mitochondrial MnSOD prevents neural apoptosis and reduces ischemic brain injury: suppression of peroxynitrite production, lipid peroxidation and mitochondrial dysfunction. J Neurosci. 1998;18:687–97.PubMedGoogle Scholar
  11. 11.
    Cadet J, Douki T, Gasparutto D, Ravanat JL. Oxidative damage to DNA: formation, measurement and biochemical features. Mutat Res. 2003;531:5–23.CrossRefPubMedGoogle Scholar
  12. 12.
    Matsuzawa A, Ichijo H. Stress-responsive protein kinases in redox-regulated apoptosis signaling. Antioxid Redox Signal. 2005;7:472–81.CrossRefPubMedGoogle Scholar
  13. 13.
    Lunec J, Holloway KA, Cooke MS, Faux S, Griffiths HR, Evans MD. Urinary 8-oxo-2V-deoxyguanosine: redox regulation of DNA repair in vivo? Free Radic Biol Med. 2002;33:875–85.CrossRefPubMedGoogle Scholar
  14. 14.
    Guoa C, Lia L, Yangb X, Menga Z, Lia F, Zhanga C. Protective effects of timosaponin B-II on high glucose-induced apoptosis in human umbilical vein endothelial cells. Environ Toxicol Pharmacol. 2013;37(1):37–44. doi: 10.1016/j.etap.2013.11.009.CrossRefGoogle Scholar
  15. 15.
    Uchiyama M, Mihara M. Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Ann Biochem. 1978;86:271–8.CrossRefGoogle Scholar
  16. 16.
    Hsing AW, Reichardt JK, Stanczyk FZ. Hormones and prostate cancer: current perspectives and future directions. Prostate. 2002;52:213–35.CrossRefPubMedGoogle Scholar
  17. 17.
    Czene K, Lichtenstein P, Hemminki K. Environmental and heritable causes of cancer among 9.6 million individuals in the Swedish Family-Cancer Database. Int J Cancer. 2002;99:260–6.CrossRefPubMedGoogle Scholar
  18. 18.
    Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals, and antioxidants in oxidative stress-induced cancer. Chem Biol Interact. 2006;160:1–40.CrossRefPubMedGoogle Scholar
  19. 19.
    Aymelek G, Erten D, Aslan S, Akinci M, Simşek B, Torun M. Lipid peroxidation and antioxidant status in blood and tissue of malignant breast tumor and benign breast disease. Cell Biol Int. 2006;30:376–80.CrossRefGoogle Scholar
  20. 20.
    Wang J, Yi J. Cancer cell killing via ROS: to increase or decrease, that is the question. Cancer Biol Ther. 2008;7:1875–84.CrossRefPubMedGoogle Scholar
  21. 21.
    Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelicano H, et al. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell. 2006;10:241–52.CrossRefPubMedGoogle Scholar
  22. 22.
    Stadtman ER, Berlett BS. Reactive oxygen-mediated protein oxidation in aging and disease. Drug Metab Rev. 1998;30:225–43.CrossRefPubMedGoogle Scholar
  23. 23.
    Arsova-Sarafinovska Z, Eken A, Matevska N, Erdem O, Sayal A, Savaser A, et al. Increased oxidative/nitrosative stress and decreased antioxidant enzyme activities in prostate cancer. Clin Biochem. 2009;42:1228–35.CrossRefPubMedGoogle Scholar
  24. 24.
    Guzel S, Kiziler L, Aydemir B, Alici B, Ataus S, Aksu A, Durak H. Association of Pb, Cd, and Se concentrations and oxidative damage-related markers in different grades of prostate carcinoma. Biol Trace Elem Res. 2012. doi: 10.1007/s12011-011-9162-2.
  25. 25.
    Pace G, Di Massimo C, De Amicis D, Corbacelli C, Di Renzo L, Vicentini C, et al. Oxidative stress in benign prostatic hyperplasia and prostate cancer. Urol Int. 2010;85:328–33.CrossRefPubMedGoogle Scholar
  26. 26.
    Ozmen H, Erulas FA, Karatas F, Cukurovali A, Yalcin O. Comparison of the concentration of trace metals (Ni, Zn, Co, Cu and Se), Fe, vitamins A, C and E, and lipid peroxidation in patients with prostate cancer. Clin Chem Lab Med. 2006;44:175–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Hye-Kyung Na and Sergiy Oliynyk, Effects of physical activity on cancer prevention, Ann. N.Y. Acad. Sci. 1229 (2011) 176–183.Google Scholar
  28. 28.
    Gaoa K, Henninga SM, Niua Y, Youssefiana AA, Seerama NP, Xub A, et al. The citrus flavonoid naringenin stimulates DNA repair in prostate cancer cells. J Nutr Biochem. 2006;17:89–95.CrossRefGoogle Scholar
  29. 29.
    Donald C. Malins,2 Paul M. Johnson, Thomas M. Wheeler, Edward A. Barker, Nayak L. Polissar, and Mark A. Vinson, Age-related Radical-induced DNA Damage Is Linked to Prostate Cancer, CANCER RESEARCH 61, 6025–6028, August 15, 2001.Google Scholar
  30. 30.
    Chen HM, Chang FR, Hsieh YC, Cheng YJ, Hsieh KC, Tsai LM, et al. A novel synthetic protoapigenone analogue, WYC02-9, induces DNA damage and apoptosis in DU145 prostate cancer cells through generation of reactive oxygen species. Free Radic Biol Med. 2011;50:1151–62.CrossRefPubMedGoogle Scholar
  31. 31.
    Rodríguez-Berriguete G, Galvis L, Fraile B, Bethencourt FR, Martínez-Onsurbe P, Olmedilla G, Paniagua R, Royuela M, Immunoreactivity to caspase-3, caspase-7, caspase-8, and caspase-9 forms is frequently lost in human prostate tumors, Human Pathology (2011), accepted 20 April 2011Google Scholar
  32. 32.
    Koka PS, Mondal D, Schultz M, Abdel-Mageed AB, Agrawal KC. Studies on molecular mechanisms of growth inhibitory effects of thymoquinone against prostate cancer cells: role of reactive oxygen species. Exp Biol Med. 2010;235:751–60.CrossRefGoogle Scholar
  33. 33.
    Curcumin-Induced Apoptosis in PC3 Prostate Carcinoma Cells Is Caspase-Independent and Involves Cellular Ceramide Accumulation and Damage to Mitochondria Hilchie AL, Furlong SJ, Sutton K, Richardson A, Robichaud MRJ, Giacomantonio CA, Ridgway ND, Hoskin DW, Nutrition and Cancer, 62, 2010, (3), 379–389.Google Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Funda Kosova
    • 1
  • Gökhan Temeltaş
    • 2
  • Zeki Arı
    • 3
  • Murat Lekili
    • 2
  1. 1.Celal Bayar University School of HealthManisaTurkey
  2. 2.Department of UrologyCelal Bayar University Medical FacultyManisaTurkey
  3. 3.Department of Medical BiochemistryCelal Bayar University Medical FacultyManisaTurkey

Personalised recommendations